We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Global Hematology Diagnostic Devices and Equipment Market to Reach USD 2.35 Billion by 2022

By LabMedica International staff writers
Posted on 03 Jan 2020
The global hematology diagnostic devices and equipment market was valued at about USD 1.9 billion in 2018 and is projected to grow to at a CAGR of 5.5% to USD 2.35 billion in 2022. More...
The market growth is driven mainly by an increase in the use of hematology diagnostic devices due to the rising prevalence of blood disorders which affect millions of people each year across the world, irrespective of age, race, and sex.

These are the latest findings of The Business Research Company (London, UK), a market research and intelligence company.

Despite its potential for rapid growth, the hematology diagnostic devices market is constrained by stringent regulation policies. Currently, the FDA regulates class I, class II, and class III hematology devices. Class I hemostasis devices are exempt from premarket notification requirements and are used only for general control. Regulations for class II devices are exempt from premarket notification requirements and they can be used for special controls. Class III is the most stringent category as it requires premarket approval (PMA).

Companies in the hematology diagnostic devices market are increasingly investing in automation technology. The advancements in automation technology are driving the demand for hematology analyzers and will continue to reduce the errors caused by manual practices in diagnostic centers. However, product recall is one of the major problems being faced by companies in the hematology diagnostic devices market and can negatively affect market growth.

Related Links:
The Business Research Company


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.